Geron (GERN) Short-term Investments (2010 - 2026)
Geron's (GERN) quarterly Short-term Investments came in at $238.2 million in Q2 2026, down 23.22% year-over-year from $310.2 million in Q2 2025, and down 2.18% quarter-over-quarter from $243.5 million in Q1 2026.
Analysis
Geron (GERN) Short-term Investments (2010 - 2026) Analysis & Trends
Geron has disclosed Short-term Investments across 17 years of filings, most recently posting $238.2 million for Q2 2026.
- In Q2 2026, Short-term Investments fell 23.22% year-over-year to $238.2 million; the TTM figure through Jun 2026 stood at $238.2 million (down 23.22% YoY), while the FY2025 annual figure was $280.4 million, down 14.41% from the prior year.
- Short-term Investments came in at $238.2 million for Q2 2026 at Geron, down from $243.5 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $327.6 million in Q4 2024 to a low of $115.9 million in Q4 2022.
- Average Short-term Investments over 5 years is $247.3 million, with a median of $265.8 million recorded in 2023.
- Year-over-year, Short-term Investments fell 24.59% in 2022 and jumped 127.5% in 2023.
- Over 5 years, Short-term Investments stood at $115.9 million in 2022, then jumped by 127.5% to $263.7 million in 2023, then gained by 24.22% to $327.6 million in 2024, then declined by 14.41% to $280.4 million in 2025, then dropped by 15.04% to $238.2 million in 2026.
- Per Business Quant data, the three most recent Short-term Investments figures were $238.2 million in Q2 2026, $243.5 million in Q1 2026, and $280.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 238.21 Mn |
| Mar 31, 2026 | 243.51 Mn |
| Dec 31, 2025 | 280.36 Mn |
| Sep 30, 2025 | 302.42 Mn |
| Jun 30, 2025 | 310.25 Mn |
| Mar 31, 2025 | 313.13 Mn |
| Dec 31, 2024 | 327.55 Mn |
| Sep 30, 2024 | 279.43 Mn |
| Jun 30, 2024 | 245.79 Mn |
| Mar 31, 2024 | 253.29 Mn |
| Dec 31, 2023 | 263.68 Mn |
| Sep 30, 2023 | 282.82 Mn |
| Jun 30, 2023 | 314.48 Mn |
| Mar 31, 2023 | 267.96 Mn |
| Dec 31, 2022 | 115.90 Mn |
| Sep 30, 2022 | 133.68 Mn |
| Jun 30, 2022 | 143.23 Mn |
| Mar 31, 2022 | 135.35 Mn |
| Dec 31, 2021 | 148.85 Mn |
| Sep 30, 2021 | 147.08 Mn |